ER

Insmed appoints Andrew Drechsler as CFO

Thursday, November 8, 2012 02:49 PM

Insmed, a biopharmaceutical company focused on inhaled therapeutics for serious lung diseases, has appointed Andrew Drechsler to the position of chief financial officer.

More... »

CEO of Sanofi designated as new president elect of EFPIA

Wednesday, November 7, 2012 01:55 PM

The European Federation of Pharmaceutical Industries and Associations (EFPIA), which represents the pharmaceutical industry operating in Europe, has designated Christopher A. Viehbacher, CEO of Sanofi, as the new president elect of EFPIA. He will take up the position as of June 2013 for a two year term.

More... »

Northwest Bio collaborates with U.K. cancer institutions for DCVaxR-Direct trial

Wednesday, November 7, 2012 11:51 AM

Northwest Biotherapeutics, a Bethesda, Md.-based biotechnology company developing DCVax personalized immune therapies for cancer, has initiated a collaboration with U.K.-based cancer institutions Sarah Cannon Research U.K. and Leaders in Oncology Care (LOC) on a phase I/II trial with DCVax-Direct for metastatic colon cancer. 

More... »

Takeda to acquire Envoy Therapeutics

Wednesday, November 7, 2012 11:24 AM

Takeda America Holdings, a subsidiary of Japanese, research-based company Takeda Pharmaceutical, has agreed to acquire Envoy Therapeutics, a privately-held drug discovery company based in Jupiter, Fla. Takeda's corporate venture arm, Takeda Ventures, participated in Envoy's series A financing in October 2009.

More... »

U.K. government awards $2.7M grant to PsiOxus cancer vaccine

Wednesday, November 7, 2012 10:57 AM

PsiOxus Therapeutics, a development stage biotechnology company based in the U.K was awarded a $2.7 million grant from the U.K. government-backed Biomedical Catalyst to initiate a phase I/II clinical trial to assess the use of ColoAd1 in the treatment of platinum-resistant, recurrent ovarian cancer.

More... »

Curie-Cancer, Harmonic to explore anti-cancer activity of several compounds

Monday, November 5, 2012 03:21 PM

Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities, and Harmonic Pharma, a French company focused on extending the therapeutic application of compounds already on the market, have entered into a research collaboration aimed at exploring the anti-cancer activity of several molecules in Harmonic’s portfolio.

More... »

Ziarco founded with Series A financing

Monday, November 5, 2012 11:01 AM

Recently founded Ziarco, a clinical-stage biotech focused on therapeutics targeting inflammatory and allergic diseases, has closed an initial $6 million tranche of Series A financing totaling $27 million. The round was led by Biotechnology Value Fund, with participation by Pfizer Venture Investments.

More... »

Nimbus Discovery names Lynch as executive chairman

Friday, November 2, 2012 03:04 PM

Nimbus Discovery, a biotechnology company based in Cambridge, Mass., has appointed Daniel S. Lynch to the company's board of directors as executive chairman. Lynch will succeed Bruce Booth, D. Phil., co-founder of Nimbus and partner at Atlas Venture, who will remain on the board.

More... »

Bayer HealthCare strengthens position in Russia

Friday, November 2, 2012 02:21 PM

Bayer HealthCare and Russian drug manufacturer Medsintez have entered into a strategic partnership to jointly manufacture and commercialize diagnostic imaging products as well as pharmaceuticals to treat infections and neural disorders.

More... »

Portola, BMS, Pfizer ink collaboration on study on reversing anticoagulation

Friday, November 2, 2012 01:57 PM

Portola Pharmaceuticals, a therapeutics company focused on thrombosis, inflammatory disease and cancer, global biopharmaceutical company Bristol-Myers Squibb (BMS) and Pfizer have signed a clinical collaboration agreement to conduct a proof-of-concept study of PRT4445 and the investigational oral Factor Xa inhibitor Elquis (apixaban).

More... »